WorldPharmaNews
  • Home
  • Business
  • Research
  • Jobs
  • Events
  • Regulatory
AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

www.astrazeneca.com

AstraZeneca RSS Channel

Filters
List of articles in category AstraZeneca
Title Published Date
AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma 24 October 2018
US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer 18 October 2018
Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer 25 September 2018
The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease 17 September 2018
Tezepelumab granted Breakthrough Therapy Designation by US FDA 07 September 2018
Selumetinib granted orphan designation in Europe for neurofibromatosis type 1 09 August 2018
Atacand to be divested to Cheplapharm in Europe 24 July 2018
Update on Phase III clinical trials of lanabecestat for Alzheimer's disease 12 June 2018
AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline 24 May 2018
AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease 11 May 2018
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
  • AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
  • FDA approves Pfizer's biosimilar, ABRILADAâ„¢ (adalimumab-afzb) for multiple inflammatory conditions
  • Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer
  • Bayer selects Pharmaron as partner organization

Research & Development

  • The gut may be involved in the development of multiple sclerosis
  • Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer
  • Investigational drugs reduce risk of death from Ebola virus disease
  • Pharmacist-led interventions may help prevent cardiovascular disease
  • A protein tag to study the immune system
  • Industry executives: Profits drive rising prices for MS drugs
  • Artificial Intelligence algorithm can learn the laws of quantum mechanics and speed up drug delivery

Conferences & Events

  • Excellent market conditions at largest ever CPhI Worldwide bodes well for global pharma in 2020
  • SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020
  • SMi's 4th Annual 3D Cell Culture
  • Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade
  • RNA Therapeutics Conference and Focus Day
  • CPhI Worldwide announces the winners of the 16th Pharma Awards
  • CPhI Annual Report predicts Europe to surpass the USA in biologic manufacturing capacity by 2023

Regulatory Affairs

  • FDA approves first generics of Gilenya
  • FDA approves novel treatment to target abnormality in sickle cell disease
  • FDA approves first treatment for inherited rare disease
  • FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease
  • FDA approves first therapy to treat patients with rare blood disorder
  1. You are here:  
  2. Home
  3. AstraZeneca

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2006 - 2017. All Rights Reserved. WORLD PHARMA JOBS | PharmaNews.eu | eHealthNews.eu | (HEALTH IT) SPACE